Tilak Mandadi
Known title: EVP, Chief Technology OfficerCIK: 0001872827
Associated companies
Transaction History
| CVS | ▼ Sell | Open Market | 69,551 | $6.2M | 5/8/2026 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 3,634 | $263K | 4/1/2026 | View on chart |
| CVS | ▲ Buy | Grant | 22,277 | $1.6M | 3/31/2026 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 6,575 | $528K | 11/30/2025 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 12,834 | $939K | 8/31/2025 | View on chart |
| CVS | ▲ Buy | Grant | 20,594 | $1.4M | 4/1/2025 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 995 | $68K | 4/1/2025 | View on chart |
| CVS | ▲ Buy | Grant | 50,125 | $3.0M | 11/30/2024 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 13,097 | $750K | 8/31/2024 | View on chart |
| CVS | ▲ Buy | Grant | 16,339 | $0 | 4/1/2024 | View on chart |
| CVS | ▼ Sell | Tax Withholding | 13,053 | $851K | 8/31/2023 | View on chart |
| CVS | ▲ Buy | Grant | 99,847 | $0 | 8/31/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
CVS Health News: Caremark Shift, Settlement Deadline, Defensive Status
CVS Caremark is changing how patients access health services, according to a recent report. The company also faces a settlement claim deadline a month away, with guidance on how to receive the funds. Analysts note that CVS is among a few defensive healthcare stocks being watched as rates remain high, and it has recently outperformed market returns.
CVS Health News: Caremark Shift, Settlement Deadline, Defensive Status. CVS Caremark is changing how patients access health services, according to a recent report. The company also faces a settlement claim deadline a month away, with guidance on how to receive the funds. Analysts note that CVS is among a few defensive healthcare stocks being watched as rates remain high, and it has recently outperformed market returns.